"Agonists of A2a Adenosine Receptors for Treating Recurrent Tumor Growth" in Patent Application Approval Process

Citation metadata

Date: Aug. 23, 2014
Publisher: NewsRX LLC
Document Type: Article
Length: 1,068 words
Lexile Measure: 1420L

Document controls

Main content

Article Preview :

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent application by the inventors Kranenburg, Onno (Utrecht, NL); van der Bilt, Jamila (Amsterdam, NL); Borel Rinkes, Inne (Utrecht, NL); Rieger, Jayson M (Charlottesville, VA), filed on October 7, 2013, was made available online on August 7, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Adenosine Therapeutics, Llc).

This patent application is assigned to Adenosine Therapeutics, Llc.

The following quote was obtained by the news editors from the background information supplied by the inventors: "In the United States, approximately 150,000 patients are diagnosed with colorectal cancer each year. About 20% of these patients have metastatic deposits of colorectal cancer in the liver only at the time of diagnosis or develop such metastases during the course of their illness. In the absence of treatment, the prognosis for patients with hepatic colorectal metastases is dismal, with 5-year survival rates of 3% or less. There is now evidence that resection of such metastases can improve the prognosis. Although liver resection is not the primary treatment for most patients with hepatic colorectal metastases, appropriate liver resection is the standard of care for treatment of patients with isolated hepatic colorectal metastases. The majority of patients experience recurrence following hepatic resection of colorectal metastases. Patients at high risk for recurrence after hepatic resection are those who present with multiple hepatic metastases (vs. single metastases), large metastatic tumors (>5 cm), a high CEA serum concentration (>200 ng/mL), a node-positive primary colorectal cancer, or synchronous tumors (primary colorectal cancer and hepatic colorectal metastases). A treatment...

Source Citation

Source Citation   

Gale Document Number: GALE|A380941485